Form 4: Moderna Director Abbas Hussain Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Director Abbas Hussain acquired stock options and restricted stock units in Moderna, Inc. on October 2, 2024.
Summary
- On October 2, 2024, Abbas Hussain, a director of Moderna, Inc., acquired stock options and restricted stock units (RSUs).
- Hussain acquired options to purchase 8,093 shares at $63.16, which will fully vest on October 2, 2025.
- He also acquired options to purchase 5,100 shares at $63.16, vesting on the earlier of May 6, 2025, or the next Annual Meeting of Stockholders.
- Additionally, Hussain acquired 1,439 RSUs that will vest on October 2, 2025.
- He also acquired 892 RSUs that will vest on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders.
- All vesting is subject to continued service.
Sentiment
Score: 6
Explanation: The document reflects standard executive compensation practices. It's neutral to slightly positive as it indicates alignment of interests between management and shareholders.
Positives
- The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
- The vesting schedules incentivize continued service and alignment with shareholder interests.
Future Outlook
The vesting schedules for the stock options and RSUs suggest a focus on long-term value creation and retention of key personnel.
Industry Context
Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain talent, aligning employee incentives with company performance.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies like BioNTech, Pfizer, and Novavax.
- The vesting schedules are typical, with vesting periods of one to four years being common to incentivize long-term commitment.
- The size of the grants would be compared to similar roles and company size within the biotech sector to determine if they are within industry norms.
Stakeholder Impact
- Shareholders may view the grants as a positive sign of incentivizing management to drive long-term value.
- Employees may see the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 10/02/2024 | Date of transaction: Acquisition of stock options and restricted stock units. |
| 10/02/2025 | 8,093 stock options and 1,439 RSUs will fully vest. |
| 05/06/2025 | 5,100 stock options and 892 RSUs will vest on the earlier of this date or Moderna's next Annual Meeting of Stockholders. |
| 10/02/2034 | Expiration date for the acquired stock options. |
| 10/04/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.